SEC Form 4 · accession 0000874015-17-000008
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stanley T Crooke
Officer — Chairman and CEO · Director
Period of report
Jan 3, 2017
Accepted (ET)
Jan 4, 2017 · 6:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 3, 2017 | M | 5,000 | $7.25 | A | 30,029 | D | |
| Common StockF1 | Jan 3, 2017 | S | 5,000 | $47.30 | D | 25,029 | D | |
| Common StockF1 | Jan 3, 2017 | M | 5,000 | $7.25 | A | 30,029 | D | |
| Common StockF1 | Jan 3, 2017 | S | 5,000 | $48.80 | D | 25,029 | D | |
| Common StockF2 | Jan 3, 2017 | M | 500 | $10.29 | A | 2,670 | I | By wife |
| Common StockF2 | Jan 3, 2017 | S | 500 | $47.30 | D | 2,170 | I | By wife |
| Common StockF2 | Jan 3, 2017 | M | 500 | $10.29 | A | 2,670 | I | By wife |
| Common StockF2 | Jan 3, 2017 | S | 500 | $48.80 | D | 2,170 | I | By wife |
| Common StockF1 | Jan 4, 2017 | M | 7,000 | $7.25 | A | 32,029 | D | |
| Common StockF1 | Jan 4, 2017 | S | 7,000 | $50.10 | D | 25,029 | D | |
| Common StockF2 | Jan 4, 2017 | M | 700 | $10.29 | A | 2,870 | I | By wife |
| Common StockF2 | Jan 4, 2017 | S | 700 | $50.10 | D | 2,170 | I | By wife |
| Common Stock | holding | — | — | — | 725,391 | I | By trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $47.34 | Jan 3, 2017 | A | 163,013 | A | Jan 3, 2018 | Jan 2, 2024 | Common Stock | 163,013 | 163,013 | D |
| Employee Stock Option (right to buy)F4 | $47.34 | Jan 3, 2017 | A | 16,157 | A | Jan 3, 2018 | Jan 2, 2024 | Common Stock | 16,157 | 16,157 | I |
| Employee Stock Option (right to buy) | $7.25 | Jan 3, 2017 | M | 10,000 | D | Jan 3, 2016 | Jan 2, 2019 | Common Stock | 10,000 | 83,462 | D |
| Employee Stock Option (right to buy) | $10.29 | Jan 3, 2017 | M | 1,000 | D | Jan 3, 2015 | Jan 2, 2018 | Common Stock | 1,000 | 4,500 | I |
| Employee Stock Option (right to buy) | $7.25 | Jan 4, 2017 | M | 7,000 | D | Jan 3, 2016 | Jan 2, 2019 | Common Stock | 7,000 | 76,462 | D |
| Employee Stock Option (right to buy) | $10.29 | Jan 4, 2017 | M | 700 | D | Jan 3, 2015 | Jan 2, 2018 | Common Stock | 700 | 3,800 | I |
Explanation of responses
- F1Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 9/21/2015.
- F2Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person's wife on 9/21/2015.
- F3Grant of 1/3/2017 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 40,753 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017.
- F4Grant of 1/3/2017 to reporting person's wife of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/3/2018. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 4,039 shares per year. Following this transaction, the option was exercisable as to 0 on 1/3/2017.